Hydroxamic Acids
Research News and Information

Sunday, November 22, 2009

Hydroxamic acids as a novel family of serine racemase inhibitors: mechanistic analysis reveals different modes of interaction with the pyridoxal-5'-phosphate cofactor.

6 Oct 2009 Mammalian serine racemase (SR) is a pyridoxal-5'-phosphate (PLP) dependent enzyme responsible for the biosynthesis of the neurotransmitter D-serine, which activates N-methyl-D-aspartate (NMDA) receptors in the CNS. Aberrant regulation of NMDA ... Read more...

Antidepressant actions of histone deacetylase inhibitors.

14 Sep 2009 Persistent symptoms of depression suggest the involvement of stable molecular adaptations in brain, which may be reflected at the level of chromatin remodeling. We find that chronic social defeat stress in mice causes a transient decrease, followed ... Read more...

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

6 Sep 2009 BACKGROUND: Histone deacetylase inhibitors (HDACi) can sensitise cancer cells to topoisomerase inhibitors by increasing their access and binding to DNA. METHODS: This phase I trial was designed to determine the toxicity profile, tolerability, and ... Read more...

Latest indexed articles for 'Hydroxamic Acids'

These are the very latest articles for this heading:

• Hydroxamic acids as a novel family of serine racemase inhibitors: mechanistic analysis reveals different modes of interaction with the pyridoxal-5'-phosphate cofactor. 6 Oct 2009
• Antidepressant actions of histone deacetylase inhibitors. 14 Sep 2009
• Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. 6 Sep 2009
• Real-time imaging of histone H4 hyperacetylation in living cells. Sep 2009
• Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. 30 Aug 2009
• KLF4 suppresses HDACi induced caspase activation and the SAPK pathway by targeting p57(Kip2). 30 Aug 2009
• Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. 30 Aug 2009
• Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. 30 Aug 2009
• Optimization of coprogen production in Neurospora crassa. 30 Aug 2009
• Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma. 30 Aug 2009
• MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. 30 Aug 2009
• Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors. 30 Aug 2009
• Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. 30 Aug 2009
• Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. 23 Aug 2009
• Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. 19 Aug 2009
• Ligand-induced changes in the structure and dynamics of Escherichia coli peptide deformylase. 16 Aug 2009
• Histone deacetylase inhibitors promote neurosteroid-mediated cell differentiation and enhance serotonin-stimulated brain-derived neurotrophic factor gene expression in rat C6 glioma cells. 13 Aug 2009
• Identification and functional characterization of the promoter of the mouse sodium-activated sodium channel Na(x) gene (Scn7a). 13 Aug 2009
• Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene. 12 Aug 2009
• N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. 11 Aug 2009

See a longer list of these articles.

Technical information about 'Hydroxamic Acids'

Definition: A class of weak acids with the general formula R-CONHOH.

Registry Number: 0

Descriptor UI: D006877

Alternative terms: Hydroxamic Acids; Acids, Hydroxamic; Hydroxamic Acid; Acid, Hydroxamic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D02.092.570.394; D02.241.511.372;

Online Note: use HYDROXAMIC ACIDS to search HYDROXAMIC ACID 1966-74

History Note: 75; was HYDROXAMIC ACID 1963-74